Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paget Disease, Extramammary × toripalimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 34 Carcinoma, Non-Small-Cell Lung 26 Esophageal Squamous Cell Carcinoma 20 Carcinoma, Hepatocellular 19 Squamous Cell Carcinoma of Head and Neck 18 Triple Negative Breast Neoplasms 17 Breast Neoplasms 16 Melanoma 15 Advanced Solid Tumor 15 Stomach Neoplasms 13 Colorectal Neoplasms 12 Uterine Cervical Neoplasms 11 Small Cell Lung Carcinoma 11 Neoplasms 10 Recurrence 9 Carcinoma, Transitional Cell 9 Carcinoma, Renal Cell 8 Solid Tumor 6 Sarcoma 6 Neoplasm Metastasis 6 Liver Neoplasms 6 Head and Neck Neoplasms 6 Esophageal Neoplasms 5 Rectal Neoplasms 4 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Ovarian Neoplasms 3 Lymphoma 3 Lung Neoplasms 3

Interventions

Specimen Handling 2 Nivolumab 2 toripalimab 1 talimogene laherparepvec 1 pembrolizumab 1 bicalutamide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Ipilimumab 1 Imiquimod 1 Fluorescein 1 CTLA-4 Antigen 1 Biopsy 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06791070 2025-01-24

RC48&J for EPD

Fujian Medical University Union Hospital

Phase 2 Recruiting

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡